aristinc 400 mg/200 ml rastvor za infuziju
doo ˝farmacija 2011˝ bihać - ciprofloksacin - rastvor za infuziju - 400 mg/200 ml - 1 ml rastvora za infuziju sadrži: 2 mg ciprofloksacina
aristinc 200 mg/100 ml rastvor za infuziju
doo ˝farmacija 2011˝ bihać - ciprofloksacin - rastvor za infuziju - 200 mg/100 ml - 1 ml rastvora za infuziju sadrži:2 mg ciprofloksacina
ciprofloxacina bioindustria l.i.m. 200 mg/100 ml rastvor za infuziju
sanmed d.o.o. banja luka - ciprofloksacin - rastvor za infuziju - 200 mg/100 ml - 1 ml rastvora za infuziju sadrži: 2 mg ciprofloksacina (u obliku ciprofloksacin laktata)
ciprofloxacina bioindustria l.i.m. 400 mg/200 ml rastvor za infuziju
sanmed d.o.o. banja luka - ciprofloksacin - rastvor za infuziju - 400 mg/200 ml - 1 ml rastvora za infuziju sadrži : 2 mg ciprofloksacina(u obliku ciprofloksacin laktata)
ciprol 500 mg/1 tableta film tableta
bosnalijek d.d. - ciprofloksacin - film tableta - 500 mg/1 tableta - 1 film tableta sadrži: 500 mg ciprofloksacina (u obliku ciprofloksacin hidrohlorida)
cipromed 500 mg/1 tableta filmom obložena tableta
pliva d.o.o.sarajevo - ciprofloksacin - filmom obložena tableta - 500 mg/1 tableta - 1 filmom obložena tableta sadrži: 500 mg ciprofloksacina (u obliku ciprofloksacinhidrohlorida)
daklinza
bristol-myers squibb pharma eeig - daclatasvir dihydrochloride - hepatitis c, kronični - antivirusni lijekovi za sustavnu uporabu - daklinza je indiciran u kombinaciji s drugim lijekovima za liječenje infekcije kroničnog hepatitisa c (hcv) kod odraslih (vidi odjeljke 4. 2, 4. 4 i 5. za specifične aktivnosti genotip hcv, vidi 4. 4 i 5.
descovy
gilead sciences ireland uc - эмтрицитабин, Тенофовир alafenamide - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (hiv-1).
inlyta
pfizer europe ma eeig - axitinib - karcinom, stanice bubrega - inhibitori протеинкиназы - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.
zydelig
gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.